Abrams, D., Y. Lévy, M.H. Losso, et al. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 2008; 361:1548–1559.

Albert, J., B. Abrahamsson, K. Nagy, E et al Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990; 4:107–12.

Alter, G., and D.H. Barouch. Natural Evolution of Broadly Neutralizing Antibodies. Cell. 2015; 161:427–428.

Ammann, A.J., and J. Levy. Laboratory investigation of pediatric acquired immunodeficiency syndrome. Clin. Immunol. Immunopathol. 1986; 40:122–7.

Ananworanich, J., T. Puthanakit, P. Suntarattiwong, K. et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS. 2014; 28:1015–1020.

Andersson, J., H. Behbahani, J. Lieberman, E. et al. Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. AIDS 1999; 13:1295–303.

Appay, V., D.F. Nixon, S.M. Donahoe, et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 2000; 192:63–75.

Apps, R., Y. Qi, J.M. Carlson, H. et al. Influence of HLA-C Expression Level on HIV Control. Science. 2013; 340:87–91.

Archin, N.M., A.L. Liberty, A.D. Kashuba, S.K. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012; 487:482–485.

Attridge, K., C.J. Wang, L. Wardzinski, R. et al. IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood. 2012; 119:4656–4664.

Autran, B., G. Carcelain, T.S. Li, C. Blanc, et al. Positive Effects of Combined Antiretroviral Therapy on CD4+ T Cell Homeostasis and Function in Advanced HIV Disease. Science. 1997; 277:112–116.

Ayala, V.I., M.T. Trivett, E.V. Barsov, et al. Adoptive Transfer of Engineered Rhesus Simian Immunodeficiency Virus-Specific CD8+ T Cells Reduces the Number of Transmitted/Founder Viruses Established in Rhesus Macaques. J. Virol. 2016. 90:9942–9952.

Bachelerie, F., A. Ben-Baruch, A.M. Burkhardt, et al. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors. Pharmacol. Rev. 2014; 66:1–79.

Bachtel, N.D., G. Umviligihozo, S. Pickering, et al. HLA-C downregulation by HIV-1 adapts to host HLA genotype. PLOS Pathog. 2018; 14:e1007257.

Banga, R., F.A. Procopio, A. Noto, G. et al. PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 2016; 22:754–761.

Benito, J.M., M. López, S. Lozano, C. et al. Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation. Clin. Exp. Immunol. 2007; 149:171–177.

Bernard, N.F., C.M. Yannakis, J.S. Lee, C.M. Tsoukas. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. J. Infect. Dis. 1999; 179:538–47.

Blazek, D., F. Teque, C. Mackewicz, M. et al. The CD8+ cell non-cytotoxic antiviral response affects RNA polymerase II-mediated human immunodeficiency virus transcription in infected CD4+ cells. J. Gen. Virol. 2016; 97:220–224.

Bloch, M.T., D.E. Smith, D. Quan, et al. The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). J. Acquir. Immune Defic. Syndr. 1999; 42:192–202.

Bonyhadi, M.L., L. Rabin, S. Salimi, et al. HIV induces thymus depletion in vivo. Nature. 1993; 363:728–32.

Bournazos, S., F. Klein, J. Pietzsch, M.S. et al. Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity. Cell. 2014; 158:1243–1253.

Bradney, A.P., S. Scheer, J.M. Crawford, S.P. et al. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J. Infect. Dis. 1999; 179:1264–7.

Brenchley, J.M., D.A. Price, and D.C. Douek. HIV disease: fallout from a mucosal catastrophe? Nat. Immunol. 2006; 7:235–239.

Brenchley, J.M., D.A. Price, T.W. Schacker, T.E. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 2006; 12:1365–71.

Brenchley, J.M., T.W. Schacker, L.E. Ruff, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 2004; 200:749–59.

Broussard, S., S. Staprans, R. White, et al. Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease. J Virol. 2001; 75:2262–75.

Brown, A., S. Gartner, T. Kawano, et al. HLA-A2 down-regulation on primary human macrophages infected with an M-tropic EGFP-tagged HIV-1 reporter virus. J Leukoc Biol. 2005; 78:675–85.

Bruner, K.M., Z. Wang, F.R. Simonetti, et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature. 2019; 566:120-125

Buggert, M., M.M. Norström, M. Salemi, et al. Functional Avidity and IL-2/Perforin Production Is Linked to the Emergence of Mutations within HLA-B*5701–Restricted Epitopes and HIV-1 Disease Progression. J. Immunol. 2014; 192:4685–4696.

Bullen, C.K., G.M. Laird, C.M. Durand, et al. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat. Med. 2014; 20:425–429.

Burton, D.R., and J.R. Mascola. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 2015; 16:571–576.

Burton, D.R., P. Poignard, R.L. Stanfield, I.A. Wilson.Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses. Science. 2012; 337:183–186.

Buzon, M.J., H. Sun, C. Li, A. et al.HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat. Med. 2014; 20:139–142.

Caldwell, R.L., B.S. Egan, and V.L. Shepherd.  HIV-1 Tat represses transcription from the mannose receptor promoter. J. Immunol. 2000; 165:7035–41.

Carrington, M., G.W. Nelson, M.P. Martin, et al. HLA and HIV-1: Heterozygote Advantage and B*35-Cw*04 Disadvantage. Science. 1999; 283:1748–1752.

Caskey, M., F. Klein, J.C.C. Lorenzi, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015; 522:487-91

Caskey, M., F. Klein, and M.C. Nussenzweig. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat. Med. 2019; 25:547.

Cattin, A., T.R. Wiche Salinas, A. et al. HIV-1 is rarely detected in blood and colon myeloid cells during viral-suppressive antiretroviral therapy. AIDS 2019; 33:1293–1306.

Cavert, W., D.W. Notermans, K. Staskus, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 1997; 276:960–4.

Center, D.M., H. Kornfeld, T.C. Ryan, W.W. Cruikshank. Interleukin 16: implications for CD4 functions and HIV-1 progression. Immunol. Today. 2000; 21:273–280.

Champagne, P., G.S. Ogg, A.S. King, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001; 410:106–11.

Chase, A.J., A.R. Sedaghat, J.R. German, et al. Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J. Virol. 2007; 81:12748–57.

Chen, H., Z.M. Ndhlovu, D. Liu, et al. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat. Immunol. 2012; 13:691–700.

Cheng, L., J. Ma, J. Li, et al. Blockade of type I interferon signaling reverses HIV-1 induced immune dysfunction and reduces HIV-1 reservoirs. J. Immunol. 017; 2198:158.3-158.3.

Chéret, A., C. Bacchus-Souffan, V. Avettand-Fenoël, et al. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. J. Antimicrob. Chemother. 2015; 70:2108-20

Cheynier, R., P. Langlade-Demoyen, M.R. Marescot, et al. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur. J. Immunol. 1992; 22:2211–7.

Chirmule, N., V.S. Kalyanaraman, C. Saxinger, et al. Localization of B-cell stimulatory activity of HIV-1 to the carboxyl terminus of gp41. AIDS Res. Hum. Retroviruses. 1990; 6:299–305.

Chiu, Y.-L., V.B. Soros, J.F. Kreisberg, et al. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature. 2005; 435:108–14.

Chiu, Y.-L., H.E. Witkowska, S.C. Hall, et al. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U. S. A. 2006; 103:15588–93.

Chomont, N., M. El-Far, P. Ancuta, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 2009; 15:893–900.

Chouquet, C., B. Autran, E. Gomard, et al. Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. AIDS. 2002; 16:2399–2407.

Ciccone, E.J., J.H. Greenwald, P.I. Lee, et al. CD4+ T Cells, Including Th17 and Cycling Subsets, Are Intact in the Gut Mucosa of HIV-1-Infected Long-Term Nonprogressors. J. Virol.

Clerici, M., J.V. Giorgi, C.C. Chou, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J. Infect. Dis. 1992; 165:1012–9.

Clerici, M., J.M. Levin, H.A. Kessler, et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA  1994; 271:42–6.

Colby, D.J., L. Trautmann, S. Pinyakorn, et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat. Med. 2018; 24:923-926

Collman, R., N.F. Hassan, R. Walker, et al. Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types. J. Exp. Med. 1989; 170:1149–63.

Colonna, M. Innate Lymphoid Cells: Diversity, Plasticity, and Unique Functions in Immunity. Immunity. 2018; 48:1104–1117.

Connick, E., D.G. Marr, X.Q. Zhang, et al. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res. Hum. Retroviruses. 1996; 12:1129–40.

Conway, J.M., and A.S. Perelson. Post-treatment control of HIV infection. Proc. Natl. Acad. Sci. 2015; 112:5467–5472.

Copeland, K.F., P.J. McKay, K.L. Rosenthal. Suppression of activation of the human immunodeficiency virus long terminal repeat by CD8+ T cells is not lentivirus specific. AIDS Res. Hum. Retroviruses. 1995; 11:1321–6.

Cruikshank, W.W., K. Lim, A.C. Theodore, et al. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J. Immunol. 1996; 157:5240–5248.

DaFonseca, S., J. Niessl, S. Pouvreau, et al. Impaired Th17 polarization of phenotypically naive CD4+ T-cells during chronic HIV-1 infection and potential restoration with early ART. Retrovirology. 2015; 12:38.

Day, C.L., D.E. Kaufmann, P. Kiepiela, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006; 443:350–4.

De Wit, S., M. Delforge, C.V. Necsoi, N. Clumeck. Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. AIDS 2011; 25:1332–1333.

Deeks, S.G. HIV: Shock and kill. Nature. 2012 487:439–440.

Del Cornò, M., M.C. Gauzzi, G. Penna, et al. Human immunodeficiency virus type 1 gp120; and other activation stimuli are highly effective in triggering alpha interferon and CC chemokine production in circulating plasmacytoid but not myeloid dendritic cells. J. Virol. 2005; 79:12597–601.

Deleage, C., A. Schuetz, W.G. Alvord, et al. Impact of early cART in the gut during acute HIV infection. JCI Insight. 2016; 1. pii: e87065.

Delwart, E.L., H.W. Sheppard, B.D. Walker, et al. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J. Virol. 1994; 68:6672–83.

Deng, K., M. Pertea, A. Rongvaux, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015; 517:381–385.

Dion, M.-L., J.-F. Poulin, R. Bordi, et al. HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity. 2004; 21:757–68.

Doitsh, G., N.L.K. Galloway, X. Geng, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014; 505:509–514.

Dominguez-Villar, M., A.-S. Gautron, M. de Marcken, et al. TLR7 induces anergy in human CD4⁺ T cells. Nat. Immunol. 2015; 16:118–128.

Douek, D. HIV disease progression: immune activation, microbes, and a leaky gut. Top. HIV Med. 2007; 15:114-7.

Douek, D.C., J.M. Brenchley, M.R. Betts, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002; 417:95–8.

Douek, D.C., R.D. McFarland, P.H. Keiser, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998; 396:690–5.

Dunham, R., P. Pagliardini, S. Gordon, et al. The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus. Blood. 2006; 108:209–17.

DuPage, M., J.A. Bluestone.  Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease. Nat. Rev. Immunol. 2016; 16:149–163.

Eckard, A.R., Y. Jiang, S.M. Debanne, et al. Effect of 24 Weeks of Statin Therapy on Systemic and Vascular Inflammation in HIV-Infected Subjects Receiving Antiretroviral Therapy. J. Infect. Dis. 2014; 209:1156–1164.

Eggena, M.P., B. Barugahare, N. Jones, et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005; 174:4407–14.

Ellery, P.J., E. Tippett, Y.-L. Chiu, et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 2007; 178:6581–9.

Elliott, J.H., F. Wightman, A. Solomon, et al. Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. PLoS Pathog. 2014; 10:e1004473.

Embretson, J., M. Zupancic, J.L. Ribas, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993; 362:359–62.

Estes, J.D. Pathobiology of HIV/SIV-associated changes in secondary lymphoid tissues. Immunol. Rev. 2013; 254:65–77.

Estes, J.D., C. Kityo, F. Ssali, et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nat. Med. 2017; 23:1271–1276.

Estes, J.D., C. Reilly, C.M. Trubey, et al. Antifibrotic Therapy in Simian Immunodeficiency Virus Infection Preserves CD4+ T-Cell Populations and Improves Immune Reconstitution With Antiretroviral Therapy. J. Infect. Dis. 2015; 211:744–754.

d’Ettorre, G., S. Baroncelli, L. Micci, et al. Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. PLoS ONE. 2014; 9:e109791.

Evans, L.A., G. Thomson-Honnebier, K. Steimer, et al.  Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV. AIDS 1989; 3:273–6.

Fausther-Bovendo, H., N. Wauquier, J. Cherfils-Vicini, et al. NKG2C is a major triggering receptor involved in the Vdelta1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells. AIDS 2008; 22:217–26.

Fellay, J., K.V. Shianna, D. Ge, et al. A whole-genome association study of major determinants for host control of HIV-1. Science. 2007; 317:944–7.

Fromentin, R., S. DaFonseca, C.T. Costiniuk, et al. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4 + T cells from ART-suppressed individuals. Nat. Commun. 2019; 18:814.

Fukazawa, Y., R. Lum, A.A. Okoye, et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 2015; 21:132–139.

Furci, L., L. Lopalco, P. Loverro, et al. Non-cytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T lymphocytes from HIV-exposed-uninfected individuals. AIDS 2002; 16:1003–8.

Furci, L., G. Scarlatti, S. Burastero, et al. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J. Exp. Med. 1997; 186:455–60.

Ganusov, V.V., N. Goonetilleke, M.K.P. Liu, et al. Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection. J. Virol. 2011; 85:10518–10528.

Gao, F., M. Bonsignori, H.-X. Liao, et al. Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell. 2014; 158:481–491.

Gao, X., A. Bashirova, A.K.N. Iversen, et al. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat. Med. 2005; 11:1290–2.

Gao, X., G.W. Nelson, P. Karacki, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 2001; 344:1668–75.

García, F., N. Climent, A.C. Guardo, et al. A Dendritic Cell–Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. Sci. Transl. Med. 2013; 5:166ra2-166ra2.

Gattinoni, L., E. Lugli, Y. Ji, et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 2011; 17:1290–1297.

Gavegnano, C., J.H. Brehm, F.P. Dupuy, et al. Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. PLoS Pathog. 2017; 13:e1006740.

Geleziunas, R., W. Xu, K. Takeda, et al. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature. 2001; 410:834–8.

George, M.D., E. Reay, S. Sankaran, and S. Dandekar. Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J. Virol. 2005; 79:2709–19.

Goh, W.C., J. Markee, R.E. Akridge, et al. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J. Infect. Dis. 1999; 179:548–57.

Gordon, S.N., N.R. Klatt, S.E. Bosinger, et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J. Immunol. 2007; 179:3026–34.

Gorochov, G., A.U. Neumann, A. Kereveur, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat. Med. 1998; 4:215–21.

Goulder, P.J., R.E. Phillips, R.A. Colbert, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 1997; 3:212–7.

Goulder, P.J.R., C. Brander, Y. Tang, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature. 2001; 412:334–338.

Goulder, P.J.R., and B.D. Walker. HIV and HLA Class I: an evolving relationship. Immunity. 2012; 37:426–440.

Halper-Stromberg, A., C.-L. Lu, F. Klein, et al. Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice. Cell. 2014; 158:989–999.

Hammond, S.A., R.C. Bollinger, P.E. Stanhope, et al. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J. Exp. Med. 1992; 176:1531–42.

Hansen, S.G., M. Piatak, A.B. Ventura, et al. Immune clearance of highly pathogenic SIV infection. Nature. 2013; 502.

Hansen, S.G., H.L. Wu, B.J. Burwitz, et al. Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E. Science. 2016; 351:714–720.

Hatziioannou, T., and D.T. Evans.  Animal models for HIV/AIDS research. Nat. Rev. Microbiol. 2012; 10:852–867.

Hazenberg, M.D., J.W. Stuart, S.A. Otto, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood. 2000; 95:249–55.

Herasimtschuk, A., J. Downey, M. Nelson, et al. Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection. Vaccine. 2014; 32:7005–7013.

Herasimtschuk, A.A., B.R. Hansen, A. Langkilde, et al. Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy. Clin. Exp. Immunol. 2013; 173:444–453.

Herzig, E., K.C. Kim, T.A. Packard, et al. Attacking Latent HIV with convertible CAR-T Cells, a Highly Adaptable Killing Platform. Cell. 2019; 179:880-894.e10.

Hessell, A.J., L. Hangartner, M. Hunter, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007 449:101–104.

Hessell, A.J., E.G. Rakasz, P. Poignard, et al. Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers. PLoS Pathog. 2009; 5:e1000433.

Hickman, H.D., G.V. Reynoso, B.F. Ngudiankama, et al. CXCR3 Chemokine Receptor Enables Local CD8+ T Cell Migration for the Destruction of Virus-Infected Cells. Immunity. 2015; 42:524–537.

Ho, D.D., A.U. Neumann, A.S. Perelson, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995; 373:123–6.

Hogan, C.M., and S.M. Hammer. Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses. Ann. Intern. Med. 2001; 134:761–76.

Hu, H., M.A. Eller, S. Zafar, et al. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. Proc. Natl. Acad. Sci. 2014; 111:13439–13444.

Hunt, P.W., J. Brenchley, E. Sinclair, et al. Relationship between T Cell Activation and CD4(+) T Cell Count in HIV-Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy. J Infect Dis. 2008; 197:126–133.

Imamichi, H., G. DeGray, D.M. Asmuth, et al. HIV-1 viruses detected during episodic blips following IL-7 administration are similar to the viruses present before and after IL-7 therapy. AIDS 2011; 25:159–164..

Iqbal, S.M., T.B. Ball, P. Levinson, et al. Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 2009; 23:1669–1677.

Jacobson, D.L., J.A. McCutchan, P.L. Spechko, et al. The evolution of lymphadenopathy and hypergammaglobulinemia are evidence for early and sustained polyclonal B lymphocyte activation during human immunodeficiency virus infection. J. Infect. Dis. 1991; 163:240–6.

Jacobson, J.M., H. Wang, R. Bordi, et al.  A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 1999. 66:399–406.

Jamieson, B.D., D.C. Douek, S. Killian, et al. Generation of functional thymocytes in the human adult. Immunity. 1999; 10:569–75.

Jenabian, M.-A., M. El-Far, K. Vyboh, et al. Immunosuppressive Tryptophan Catabolism and Gut Mucosal Dysfunction Following Early HIV Infection. J. Infect. Dis. 2015; 212:355–366. 7.

Jin, X., D.E. Bauer, S.E. Tuttleton, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 1999; 189:991–8.

Juffermans, N.P., A. Verbon, D.P. Olszyna, et al. Thalidomide Suppresses Up-Regulation of Human Immunodeficiency Virus Coreceptors CXCR4 and CCR5 on CD4+ T Cells in Humans. J. Infect. Dis. 2000; 181:1813–1816.

Kalams, S.A., S.P. Buchbinder, E.S. Rosenberg, et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J. Virol. 1999; 73:6715–20.

Kalams, S.A., P.J. Goulder, A.K. Shea, et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 1999; 73:6721–8.

Kalams, S.A., S.D. Parker, M. Elizaga, et al. Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery. J. Infect. Dis. 2013; 208:818–829.

Kalams, S.A., and B.D. Walker.  The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 1998; 188:2199–204.

Kanazawa, S., T. Okamoto, and B.M. Peterlin. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity. 2000; 12:61–70.

Kasang, C., A. Ulmer, N. Donhauser, et al. HIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patients. BMC Infect. Dis. 2012; 12:14.

Kaslow, R.A., M. Carrington, R. Apple, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV–1 infection. Nat. Med. 1996; 2:405–411.

Kaufmann, D.E., D.G. Kavanagh, F. Pereyra, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 2007; 8:1246–1254.

Kaul, R., T. Dong, F.A. Plummer, et al. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J. Clin. Invest. 2001; 107:1303–10.

Kaul, R., S.L. Rowland-Jones, J. Kimani, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J. Clin. Invest. 2001; 107:341–9.

Kaur, R., R. Bedimo, M.B. Kvanli, et al. A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil. AIDS Res. Ther. 2006; 3:16.

Kawashima, Y., K. Pfafferott, J. Frater, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature. 2009; 458:641–645.

Khoury, G., J.L. Anderson, R. Fromentin, et al. Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T-cells in HIV-infected individuals on antiretroviral therapy. AIDS. 2016; 30:1511–1520.

Kim, Y., J.L. Anderson, and S.R. Lewin. Getting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV. Cell Host Microbe. 2018; 23:14–26.

Klein, L., B. Kyewski, P.M. Allen, and K.A. Hogquist. Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see). Nat. Rev. Immunol. 2014; 14:377–391.

Koenig, S., A.J. Conley, Y.A. Brewah, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1995; 1:330–6.

Koup, R.A., J.T. Safrit, Y. Cao, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 1994; 68:4650–5.

Kovacs, J.A., R.A. Lempicki, I.A. Sidorov, et al. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J. Exp. Med. 2001; 194:1731–41.

Kumar, B.V., T.J. Connors, and D.L. Farber. Human T Cell Development, Localization, and Function throughout Life. Immunity. 2018; 48:202–213.

Kvale, D., V. Ormaasen, A.-M.B. Kran, et al. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. AIDS 2006; 20:813–820.

Lajoie, J., K. Birse, L. Mwangi, et al. Using safe, affordable and accessible non-steroidal anti-inflammatory drugs to reduce the number of HIV target cells in the blood and at the female genital tract. J. Int. AIDS Soc. 2018; 21:e25150.

Lang, W., H. Perkins, R.E. Anderson, et al. Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J. Acquir. Immune Defic. Syndr. 1989; 2:63–9.

Langlade-Demoyen, P., N. Ngo-Giang-Huong, F. Ferchal, and E. Oksenhendler.  Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J. Clin. Invest. 1994; 93:1293–7.

Lathey, J.L., J. Tsou, K. Brinker, et al. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. J. Infect. Dis. 1999; 180:344–50.

Lederman, M.M., L. Smeaton, K.Y. Smith, et al. Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV‐1 Infection Starting Suppre